Literature DB >> 20665252

Epstein-Barr virus-infected subcutaneous panniculitis-like T-cell lymphoma associated with methotrexate treatment.

Yuiko Nemoto1, Ayuko Taniguchi, Mikio Kamioka, Yoko Nakaoka, Makoto Hiroi, Akihito Yokoyama, Hideaki Enzan, Masanori Daibata.   

Abstract

Methotrexate-associated lymphoproliferative disorder (MTX-LPD) is a lymphoid proliferation or lymphoma in patients treated with MTX. We report a case of Epstein-Barr virus (EBV)-positive subcutaneous panniculitis-like T-cell lymphoma (SPTCL) in a 60-year-old Japanese man treated with MTX for rheumatoid arthritis (RA). SPTCL is a rare cytotoxic T-cell lymphoma characterized by involvement of subcutaneous fat mimicking panniculitis. The patient, who had been on MTX therapy for RA, manifested high fever and lumbago. Physical examination showed multiple subcutaneous nodules on the trunk including axillary and inguinal regions. Biopsy of the inguinal nodule showed profuse infiltration of CD8(+) T-cell lymphoma cells in the subcutaneous adipose tissues. A diagnosis of SPTCL was made according to the diagnostic criteria of World Health Organization classification. EBV-encoded small RNA in situ hybridization revealed that the lymphoma cells contained EBV genome. The cells were positive for EBV latent membrane protein 1, but not for EBNA2. After discontinuation of MTX, the nodules regressed spontaneously. Studies have reported that most MTX-LPDs are B-cell type lymphomas and Hodgkin lymphoma. To the best of our knowledge, EBV-positive SPTCL has not been reported in patients receiving MTX. Our case emphasizes the importance of clinical and virological characterization of MTX-associated SPTCL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20665252     DOI: 10.1007/s12185-010-0642-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  20 in total

Review 1.  EBV and malignant lymphoma with special emphasis on pyothorax-associated lymphoma.

Authors:  K Aozasa; H Kanno; H Miwa; Y Tomita
Journal:  Curr Top Microbiol Immunol       Date:  2001       Impact factor: 4.291

2.  Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication.

Authors:  Yoshihiko Hoshida; Jing-Xian Xu; Shigeki Fujita; Itsuko Nakamichi; Jun-Ichiro Ikeda; Yasuhiko Tomita; Shin-Ichi Nakatsuka; Jun-Ichi Tamaru; Atsushi Iizuka; Tsutomu Takeuchi; Katsuyuki Aozasa
Journal:  J Rheumatol       Date:  2006-11-15       Impact factor: 4.666

3.  Subcutaneous panniculitis-like T-cell lymphoma in a patient receiving etanercept for rheumatoid arthritis.

Authors:  C Michot; V Costes; D Gerard-Dran; B Guillot; B Combes; O Dereure
Journal:  Br J Dermatol       Date:  2009-02-16       Impact factor: 9.302

4.  Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.

Authors:  M Rowe; A L Lear; D Croom-Carter; A H Davies; A B Rickinson
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

5.  Latent Epstein-Barr virus infection is frequently detected in subcutaneous lymphoma associated with hemophagocytosis but not in nonfatal cytophagic histiocytic panniculitis.

Authors:  K Iwatsuki; H Harada; M Ohtsuka; G Han; F Kaneko
Journal:  Arch Dermatol       Date:  1997-06

6.  Age-related EBV-associated B-cell lymphoproliferative disorders: diagnostic approach to a newly recognized clinicopathological entity.

Authors:  Yoshie Shimoyama; Naoko Asano; Masaru Kojima; Satoko Morishima; Kazuhito Yamamoto; Takashi Oyama; Tomohiro Kinoshita; Shigeo Nakamura
Journal:  Pathol Int       Date:  2009-12       Impact factor: 2.534

7.  Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.

Authors:  P Geborek; A Bladström; C Turesson; A Gulfe; I F Petersson; T Saxne; H Olsson; L T H Jacobsson
Journal:  Ann Rheum Dis       Date:  2005-02-04       Impact factor: 19.103

8.  The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.

Authors:  Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Rheum       Date:  2007-05

Review 9.  Cytophagic histiocytic panniculitis--a syndrome associated with benign and malignant panniculitis: case comparison and review of the literature.

Authors:  A J Craig; H Cualing; G Thomas; C Lamerson; R Smith
Journal:  J Am Acad Dermatol       Date:  1998-11       Impact factor: 11.527

10.  Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas.

Authors:  Wen-hai Feng; Jeffrey I Cohen; Steven Fischer; Li Li; Michael Sneller; Raphael Goldbach-Mansky; Nancy Raab-Traub; Henri-Jacques Delecluse; Shannon C Kenney
Journal:  J Natl Cancer Inst       Date:  2004-11-17       Impact factor: 13.506

View more
  2 in total

Review 1.  Progressive and painful wound as a feature of subcutaneous panniculitis-like T-cell lymphoma (SPTCL): report of a case and review of literature.

Authors:  Qixia Jiang; Yuanling Xu; Xiaohua Li; Qing Peng; Hui Cai; Jiandong Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

2.  Mature T/NK-cell lymphoproliferative disease and Epstein-Barr virus infection are more frequent in patients with rheumatoid arthritis treated with methotrexate.

Authors:  Seiji Kondo; Kazuki Tanimoto; Kozue Yamada; Goichi Yoshimoto; Eiichi Suematsu; Tomoaki Fujisaki; Yumi Oshiro; Kazuo Tamura; Morishige Takeshita; Seiichi Okamura
Journal:  Virchows Arch       Date:  2013-03-14       Impact factor: 4.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.